Document Detail


Clinical value of (11)C-methionine PET/CT in patients with plasma cell malignancy: comparison with (18)F-FDG PET/CT.
MedLine Citation:
PMID:  23340595     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: PET/CT using FDG has been widely used for the imaging of various malignant tumours, including plasma cell malignancy (PCM), but (11)C-methionine (MET), as a radiolabelled amino acid tracer, may also be useful because PCM is able to activate protein synthesis. The purpose of this study was to evaluate the clinical value of PET/CT imaging using MET in PCM, including multiple myeloma, compared with that of FDG PET/CT. METHODS: The study group comprised 20 patients with histologically proven PCM who underwent FDG PET/CT and MET PET/CT scans before (n = 6) or after (n = 14) treatment. Semiquantitative analysis was performed on a lesion basis. We also visually evaluated the scans qualitatively using a five-point scale (0, negative; 1, probably negative; 2, equivocal; 3, probably positive; 4, positive) on a lesion and a patient basis. The results were compared between the two scans. RESULTS: Active PCM was confirmed in 15 patients, including two patients with extramedullary lesions. Uptake of MET tended to be higher (maximum standardized uptake value 10.3 ± 5.6, mean ± SD) than that of FDG (3.4 ± 2.7, p < 0.001), and more lesions of grade 3 or 4 were depicted by MET (MET 156 lesions vs. FDG 58 lesions). On a patient basis, two patients were accurately diagnosed only by MET. In the remaining 18 patients, consistent results were obtained, but potential upgrade of staging or restaging was necessary in 6 of 11 positive patients because more abnormal lesions were demonstrated by MET. The patient-based sensitivity, specificity and accuracy of MET for restaging were 89 %, 100 % and 93 %, respectively, while those of FDG were 78 %, 100 % and 86 %, respectively. CONCLUSION: MET revealed an equal or greater number of lesions in PCM than FDG. MET may be especially useful when negative or inconclusive findings are obtained by FDG despite highly suspicious indications of recurrence.
Authors:
Yuji Nakamoto; Kensuke Kurihara; Masatoshi Nishizawa; Kouhei Yamashita; Koya Nakatani; Tadakazu Kondo; Akifumi Takaori-Kondo; Kaori Togashi
Related Documents :
11230665 - Hemangiomas of the fingers: mr imaging evaluation.
8163435 - Duodenal leiomyosarcoma.
7862965 - The striated cerebellum: an mr imaging sign in lhermitte-duclos disease (dysplastic gan...
9351115 - Neurosarcoma of the face: mri.
21653595 - Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis...
12432115 - Soft-tissue and osseous impingement syndromes of the ankle: role of imaging in diagnosi...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-23
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  -     ISSN:  1619-7089     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyo-Ku, Kyoto, 606-8507, Japan, ynakamo1@kuhp.kyoto-u.ac.jp.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cerv...
Next Document:  A mild method for generation of o-quinone methides under basic conditions. The facile synthesis of t...